GO
Loading...

Enter multiple symbols separated by commas

Biotechnology

More

  • Nasdaq Check: Valeant-Bausch & Lomb Deal?   Friday, 24 May 2013 | 1:30 PM ET
    Nasdaq Check: Pandora Shares Up

    Shares of Pandora are up after the company reported earnings, reports CNBC's Seema Mody. And there are reports a deal between Valeant Pharmaceuticals and Bausch & Lomb could be completed as early as next week.

  • Cramer’s Homework Uncovers Stock Concerns Friday, 26 Apr 2013 | 6:45 PM ET
    Cramer’s Homework: Less Familiar Stocks, but Less Attractive?

    Following is Cramer's homework. And he's concerned about a few of the stocks he's just researched.

  • Amgen's Stock Slammed by Disappointing Sales Tuesday, 23 Apr 2013 | 7:13 PM ET
    amgen-200.jpg

    Amgen's stock fell sharply in after-hours trading after it reported sales that fell short of Wall Street's expectations.

  • R&D For Your Portfolio: 3 Stocks in 3 Sectors   Wednesday, 17 Apr 2013 | 7:44 AM ET
    R&D For Your Portfolio: 3 Stocks in 3 Sectors

    Mark Lehmann, JMP Securities president, provides investment strategies that include a biotech company with a promising drug to fight a rare form of Leukemia.

  • San Diego's Biotech Boom   Wednesday, 10 Apr 2013 | 2:26 PM ET

    Road trip! Road trip! In the second stop, CNBC's Brian Sullivan reports on the biotech boom in San Diego.

  • San Diego Mayor: We've Diversified   Wednesday, 10 Apr 2013 | 2:18 PM ET
    San Diego Mayor: We've Diversified

    San Diego Mayor Bob Filner (D) discusses the growing sectors in the city, rising home prices, and the burgeoning biotech industry.

  • Refining America's Finest City   Wednesday, 10 Apr 2013 | 2:13 PM ET
    Refining America's Finest City

    CNBC's Jane Wells reports on business in San Diego, how the city has come back from the brink of bankruptcy, and the diversity of the economy. Just the same, taxes are among the highest in the country.

  • Why We're In San Diego   Wednesday, 10 Apr 2013 | 2:00 PM ET
    Why We're In San Diego

    San Diego has the 2nd largest biotech industry in the U.S. CNBC's Brian Sullivan is there to check it out.

  • Biogen IDEC CEO on Multiple Sclerosis Pill   Thursday, 28 Mar 2013 | 4:35 PM ET
    Biogen IDEC CEO on Multiple Sclerosis Pill

    Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.

  • Nasdaq Hits Lowest Level Since Jan 15   Tuesday, 26 Feb 2013 | 1:48 PM ET
    Nasdaq Hits Lowest Level Since Jan 15

    It is the 95th consecutive trading session in which Apple shares trade below its 50-day moving average, reports CNBC's Seema Mody.

  • BlackBerry Shares Up   Monday, 25 Feb 2013 | 3:43 PM ET
    BlackBerry Shares Up

    CNBC's Seema Mody reports BlackBerry is up today after reports that BBerry 10 is selling faster than expected.

  • J&J Knew About Widespread Hip Implant Failures: Audit Wednesday, 23 Jan 2013 | 9:52 AM ET
    A Smart Bet on Johnson & Johnson?

    An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.

  • Top Biotech Trades   Thursday, 10 Jan 2013 | 5:53 PM ET
    Top Biotech Trades

    Biotech stocks are outperforming the major indices, and are up 3 percent over the past week. CNBC's Seema Mody is tracking which stocks are trending on Twitter.

  • Eli Lilly will be "very challenged" by the loss of exclusivity on several blockbuster drugs, CEO John Lechleiter told CNBC on Tuesday, but added the company can manage its growth in response.

  • Charles River Laboratories CEO on Drug Development   Wednesday, 9 Jan 2013 | 6:25 PM ET
    Charles River Laboratories CEO on Drug Development

    Charles River Laboratories CEO James Foster discusses competition in the drug market, drug patents and where his business is headed in 2013.

  • Biotech's a Buy, but Hold Off on HMOs: Fund Manager Wednesday, 9 Jan 2013 | 2:02 PM ET
    'Rare Good News' on Health Care Retirement Savings: Study

    Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.

  • Health Care Stocks For an Ailing Portfolio   Wednesday, 9 Jan 2013 | 7:35 AM ET
    Health Care Stocks For an Ailing Portfolio

    "As a group, biotech is the place to be this year," said," Les Funtleyder, Poliwogg fund manager, discussing where to find attractive health care opportunities in 2013.

  • BioMarin's CEO On Its Product Pipeline   Tuesday, 8 Jan 2013 | 2:20 PM ET
    BioMarin's CEO On Its Product Pipeline

    The iShare Biotech ETF is up 32 percent over the past year. Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses the reason behind his company behind up 24.9 percent in the last 3 months.

  • Biotech Stocks Rally   Tuesday, 8 Jan 2013 | 1:32 PM ET
    Biotech Stocks Rally

    CNBC's Seema Mody reports the pharmaceutical and biotech sectors rally as the JPMorgan conference kicks off its second day.

  • Building the Next Big Biotech   Monday, 7 Jan 2013 | 10:20 AM ET
    Building the Next Big Biotech

    Richard Pops, chairman & CEO at Alkermes, talks with CNBC's David Faber about positive developments in two key treatments in the company's pipeline.